openPR Logo
Press release

US Breast Cancer Drug Market US Breast Cancer Sales Report 2022

07-11-2017 12:25 PM CET | Health & Medicine

Press release from: Kuick Resarch

US Breast Cancer Drug Market US Breast Cancer Sales Report 2022

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Report Table of Contents

1. US Cancer Prevalence Rate
1.1 Overview
1.2 Glimpse of Past Cancer Incidences
1.3 Current Drifts in Cancer Frequencies
1.4 Estimated Future Cancer Occurrences

2. US Breast Cancer Tendencies
2.1 Indication
2.2 Breast Cancer Historical Incidences
2.3 Recent inclinations in Breast Cancer
2.4 Breast Cancer Frequencies over Age & Race

3. Breast Cancer Risk Undercurrents
3.1 Hormonal Aspects
3.2 Family History & Genetic Predisposition
3.3 Cumulative Age & Elevated Risk
3.4 Management of Breast Cancer

4. US Breast Cancer Drug Market Outline
4.1 Topographical Arcade Sales
4.2 HER-2 Positive Drug Market

5. US Breast Cancer Drug Market Dynamics
5.1 Breast Cancer Market Accelerative Parameters
5.2 Breast Cancer Market Challenges

6. US Breast Cancer Drug Market Future Aspects

US Breast Cancer Marketed Drugs Clinical Insight by Company & Patent Analysis

7. Eribulin (Halaven)
7.1 Clinical Introduction
7.2 Brand Names
7.3 Recording & Reporting Of Clinical Adverse Events

8. Trastuzumab Emtansine (Kadcyla)
8.1 Clinical Introduction
8.2 Brand Names
8.3 Recording & Reporting Of Clinical Adverse Events

9. Palbociclib (Ibrance)
9.1 Clinical Introduction
9.2 Brand Names
9.3 Recording & Reporting Of Clinical Adverse Events

10. Pertuzumab (Omnitarg & Perjeta)
10.1 Clinical Introduction
10.2 Brand Names
10.3 Recording & Reporting Of Clinical Adverse Events

11. Gadobutrol (Gadavist, Gadovist & Gadovist 1.0)
11.1 Clinical Introduction
11.2 Brand Names
11.3 Recording & Reporting Of Clinical Adverse Events

12. Lapatinib (Tykerb)
12.1 Clinical Introduction
12.2 Brand Names
12.3 Recording & Reporting Of Clinical Adverse Events

13. Tamoxifen Oral Liquid (Soltamox)
13.1 Clinical Introduction
13.2 Brand Names
13.3 Recording & Reporting Of Clinical Adverse Events

14. Fulvestrant (Faslodex)
14.1 Clinical Introduction
14.2 Brand Names
14.3 Recording & Reporting Of Clinical Adverse Events

15. Anastrozole (Arimidex)
15.1 Clinical Introduction
15.2 Brand Names
15.3 Recording & Reporting Of Clinical Adverse Events

16. Ixabepilone (Ixempra)
16.1 Clinical Introduction
16.2 Brand Names
16.3 Recording & Reporting Of Clinical Adverse Events

17. Toremifene (Fareston)
17.1 Clinical Introduction
17.2 Brand Names
17.3 Recording & Reporting Of Clinical Adverse Events

18. Letrozole (Femara)
18.1 Clinical Introduction
18.2 Brand Names
18.3 Recording & Reporting Of Clinical Adverse Events

19. Raloxifene (Celvista, Evista, Optruma & Sevista (raloxifene))
19.1 Clinical Introduction
19.2 Brand Names

20. Exemestane (Aromasin)
20.1 Clinical Introduction
20.2 Brand Names
20.3 Recording & Reporting Of Clinical Adverse Events

21. Vitamin B12 Fluorescent-Analogues (CobalaFluor Green & CobalaFluor Red)
21.1 Clinical Introduction
21.2 Brand Names

22. Trastuzumab Companion Diagnostic (HER2 CISH pharmDx)
22.1 Clinical Introduction
22.2 Brand Names

23. Fluoxymesterone
23.1 Clinical Introduction
23.2 Recording & Reporting Of Clinical Adverse Events

24. Competitive Landscape
24.1 Agilent Technologies
24.2 AstraZeneca
24.3 Bayer HealthCare Pharmaceuticals
24.4 Bristol-Myers Squibb
24.5 Eisai Co Ltd
24.6 Eli Lilly
24.7 Novartis
24.8 Onyx Pharmaceuticals
24.9 Orion
24.10 Perrigo
24.11 Pfizer
24.12 Roche

Download Report: https://www.kuickresearch.com/report-US-Breast-Cancer-Drug-Market-Outlook-2022.php

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release US Breast Cancer Drug Market US Breast Cancer Sales Report 2022 here

News-ID: 618781 • Views: 313

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases